NBQX is a highly selective and competitive AMPA receptor antagonist. IC50 & Target: AMPA receptor^[1] In Vitro: NBQX has a high affinity for AMPA and kainate binding sites with little or no affinity for the glutamate recognition site on the NMDA receptor complex^[1]. In Vivo: NBQX is neuroprotective in a focal ischaemia model in the rat when given as an i.v. bolus dose of 30 mg/kg at the time of MCA occlusion and again at 1 h post occlusion^[1]. NBQX provides potent anticonvulsant protection against AMPA. The ED₅₀ values for the protection against AMPA-induced seizures by NBQX (30 min, i.p.) is 23.6 (11.6- 48.0)^[2].